- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04291859
Lu AF28996 in Participants With Parkinson's Disease (PD)
Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Email contact via H. Lundbeck A/S
- Phone Number: +45 36301311
- Email: LundbeckClinicalTrials@Lundbeck.com
Study Locations
-
-
-
Leeuwarden, Netherlands, 8934 AD
- Completed
- QPS Netherlands BV
-
-
-
-
Florida
-
Hallandale Beach, Florida, United States, 33009
- Recruiting
- Velocity
-
-
Georgia
-
Atlanta, Georgia, United States, 30331
- Completed
- Atlanta Center for Medical Research
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Recruiting
- Quest Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Part A
- Participants diagnosed with idiopathic PD (consistent with the UK PD Society Brain Bank Criteria for the Diagnosis of PD), with not more than 1 first-degree relative who has PD.
- Participants must have a Modified Hoehn and Yahr score ≤4 in the OFF state and ≤3 in the ON state, and a Mini Mental State Examination score >25.
- The OFF/ON amplitude on the MDS-UPDRS Part III at screening must be minimum 30% difference.
- Participants must experience recognizable and predictable motor fluctuations (with at least 1.5 hours of OFF periods in the awake time, including predictable morning OFF episodes), causing clinically significant disability during the 7-week Screening Period, as evaluated by the investigator. This will be documented using a participant ON/OFF state registration over 3 consecutive days prior to enrolment.
- Allowed concomitant medication for PD during the study includes levodopa, monoamine oxidase B inhibitors, COMT inhibitors, anticholinergics, and amantadine. Dopamine agonists are not allowed and should be discontinued ≥4 weeks prior to dosing with Lu AF28996 and until the end of the study.
Part B and Part C
- Participants diagnosed with idiopathic PD (consistent with the UK PD Society Brain Bank Criteria for the Diagnosis of PD), with not more than 1 first-degree relative who has PD.
- Participants must have a Modified Hoehn and Yahr score ≥2 to ≤4 in the OFF state and ≤3 in the ON state, a MDS-UPDRS Part IV, 4.5 score of 1 or 2, and a MDS-UPDRS Part IV, 4.2 score ≥2 (at least mild functional impact), and a Mini Mental State Examination score >25 at the Screening Visit.
- Participants must currently have a good response to levodopa and be receiving a stable dose of levodopa (≥3 doses per day of levodopa/dopa decarboxylase inhibitor therapy or ≥3 doses per day of levodopa Extended-Release Capsules and LEDD between 400 and 1600, inclusive) for at least 4 weeks prior to screening.
- Participants must experience recognizable and predictable motor fluctuations (with ≥3 hours of OFF periods in the awake time, including predictable morning OFF episodes), causing clinically significant disability during 3 months prior to enrolment, as evaluated by the investigator. The criteria will be documented using Hauser Diary over 3 consecutive days prior to enrolment.
- Participants must experience ≥1 hour daily ON time with troublesome dyskinesia (TD) in the awake time (TD/24 hours while awake) during the last 3 months prior to enrolment as evaluated by the investigator. The criteria will be documented using the Hauser Diary over 3 consecutive days prior to enrolment.
- Allowed concomitant medication for PD during the study includes levodopa, dopamine agonists, if allowed daily dose, monoamine oxidase B inhibitors, COMT inhibitors, anticholinergics, and amantadine.
Exclusion Criteria:
- The participant has or had one or more of the following conditions that are considered clinically relevant in the context of the study; other neurological disorder, psychiatric disorder, seizure disorder or encephalopathy, respiratory disease, hepatic impairment or renal insufficiency, metabolic disorder, endocrinological disorder, haematological disorder, infectious disorder, any clinically significant immunological condition, or a history of narrow-angle glaucoma.
- Participant has been treated with apomorphine (pen/pump), or levodopa/carbidopa intestinal gel (LCIG), within 6 weeks prior to the Baseline Visit.
- Participants formerly treated with oral or transdermal dopamine agonists must have discontinued 4 weeks prior to screening.
- Participant has a history of Dopamine Agonist Withdrawal Syndrome (DAWS) when dopamine agonists were previously discontinued or reduced.
Other inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lu AF28996
Participants will receive ascending oral doses of Lu AF28996 OD for 14 days (Day 1 to Day 14) in all OD Cohorts 1-4 (5). On Day 15, the participant will initiate down-titration of Lu AF28996 as per Investigator's judgement. For the BID Cohort A1, participants will receive Lu AF28996 BID for 24 days (Day 1 to Day 24), followed by down-titration as per Investigator's judgement. For the BID Cohort A2, participants will receive Lu AF28996 BID for 39 days (Day 1 to Day 39), followed by down-titration as per Investigator's judgement. For Part B BID Cohorts B1 and B2, participants will receive Lu AF28996 BID for up to 49 days, followed by down-titration as per Investigator's judgement. For Part C TID Cohorts C1 and C2, participants will receive Lu AF28996 for up to 49 days, followed by down-titration as per Investigator's judgement. |
capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Treatment-emergent Adverse Events
Time Frame: From Baseline to Day 62
|
Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)
|
From Baseline to Day 62
|
Amount of Lu AF28996, Lu AF28995, Lu AF29308, and Lu AF29309 Excreted in Urine
Time Frame: 0 (predose) to 24 hours postdose on Day 1 to Day 62
|
0 (predose) to 24 hours postdose on Day 1 to Day 62
|
|
AUC(last) of Lu AF28996
Time Frame: 0 (predose) to 24 hours postdose on Day 1 to Day 41
|
Area under the plasma concentration time curve from zero to last quantifiable plasma concentration
|
0 (predose) to 24 hours postdose on Day 1 to Day 41
|
AUC(0-24h) of Lu AF28996
Time Frame: 0 (predose) to 24 hours postdose on Day 1 to Day 41
|
Area under the plasma concentration time curve from zero to 24 hours post dose
|
0 (predose) to 24 hours postdose on Day 1 to Day 41
|
Cmax of Lu AF28996
Time Frame: 0 (predose) to 24 hours postdose on Day 1 to Day 41
|
Maximum observed plasma concentration of Lu AF28996
|
0 (predose) to 24 hours postdose on Day 1 to Day 41
|
CL/F of Lu AF28996
Time Frame: 0 (predose) to 24 hours postdose on Day 1 to Day 41
|
Oral clearance for Lu AF28996 in plasma
|
0 (predose) to 24 hours postdose on Day 1 to Day 41
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Email contact via H. Lundbeck A/S, LundbeckClinicalTrials@Lundbeck.com
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18252A
- 2019-001280-77 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Lu AF28996
-
H. Lundbeck A/SCompletedParkinson DiseaseJapan
-
H. Lundbeck A/SNot yet recruitingHealthy ParticipantsUnited Kingdom
-
H. Lundbeck A/STerminatedAlzheimer DiseaseAustria, Finland, Sweden
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompleted
-
OHSU Knight Cancer InstituteNovartis; Oregon Health and Science UniversityNot yet recruitingAnatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Recurrent Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMetastatic Adrenal Gland Pheochromocytoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Locally Advanced Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Metastatic Parathyroid Gland Carcinoma and other conditionsUnited States